野村发表研究报告指，预计石药集团(01093.HK) 2025年第四财季收入按年增长20%至76亿元人民币(下同)，略胜于市场预测的74亿元。该行又预期，集团的成品药销售额将按年微降1%至50亿元，合作收入则为11亿元。另该行料集团毛利率按年增0.3个百分点至68.5%；经营溢利率料为19%；净利润料为13亿元。至于2026财年，该行预计石药集团收入按年增14%至312亿元，由于将公司的毛利率及...
Source Link野村发表研究报告指，预计石药集团(01093.HK) 2025年第四财季收入按年增长20%至76亿元人民币(下同)，略胜于市场预测的74亿元。该行又预期，集团的成品药销售额将按年微降1%至50亿元，合作收入则为11亿元。另该行料集团毛利率按年增0.3个百分点至68.5%；经营溢利率料为19%；净利润料为13亿元。至于2026财年，该行预计石药集团收入按年增14%至312亿元，由于将公司的毛利率及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.